Recce Pharmaceuticals Signs Distribution Agreement for R327 Diabetic Foot Gel Across MENA

Why It Matters

The partnership gives Recce a fast‑track to one of the world’s highest‑diabetes burden markets, unlocking significant revenue potential and advancing its anti‑infective platform against antimicrobial‑resistant infections.

Key Takeaways

• $5 million upfront fee and milestones total up to $5 million for R327G deal
• R327G priced at $1,500 per treatment, 30% net sales to Recce
• 6% royalty triggers after $50 million annual net sales
• 10‑year exclusive rights cover Saudi Arabia, Egypt, GCC, Morocco, Algeria
• Diabetes affects 84 million in MENA; DFIs high unmet need

Pulse Analysis

Diabetic foot infections (DFIs) represent a costly complication of the diabetes epidemic, especially in the Middle East and North Africa where prevalence exceeds 17%. With more than 84 million residents living with diabetes, the region faces a pressing need for effective, locally available therapies. Traditional antibiotics are increasingly hampered by antimicrobial resistance, creating a market gap that novel anti‑infective agents like Recce's R327 gel are poised to fill.

Recce's new licensing agreement taps a well‑established Middle Eastern distributor that operates across 30+ markets and holds deep relationships in dermatology, endocrinology and infectious disease channels. The 10‑year exclusive rights cover Saudi Arabia, Egypt, Algeria, Morocco and the GCC, delivering an upfront $5 million fee plus milestone payments. Financially, the $1,500 per‑treatment price point and a 30% share of net sales, together with a 6% royalty after $50 million in annual revenue, set a clear upside trajectory. The partnership also accelerates Recce's regulatory pathway, as the distributor’s market access can streamline product registration and reimbursement discussions in Saudi Arabia, the region’s largest diabetes market.

Beyond immediate sales, the deal underscores the strategic relevance of Recce's anti‑infective platform amid rising concerns over drug‑resistant pathogens. By positioning R327G as a next‑generation solution for DFIs, Recce not only addresses a high‑unmet‑need segment but also builds credibility for its broader pipeline. Investors are likely to view the MENA rollout as a catalyst for revenue diversification and a proof point for the company’s ability to commercialise innovative therapies in emerging markets, potentially boosting its valuation and funding prospects.